Multimodal brain imaging demonstrates that both amyloid burden and glucose metabolism predict the severity of cognitive impairment in patients with Alzheimer’s disease

Abstract Background The purpose of this study is to assess brain glucose metabolism and Amyloid‐β burden in patients with Alzheimer’s disease 3 Tesla PET/MR imaging seek possible relation findings the extent cognitive impairment. Method 45 consecutive subjects memory complaints were evaluated a detailed neuropsychological test battery F18‐Fluorodeoxyglucose(FDG)‐PET/MRI F18‐Flutemetamol‐PET/MRI scans. modalities performed hybrid 3T PET / MR camera at maximum 7 days intervals. Images visually by two nuclear medicine experts. centiloid scores calculated through amyloid standardized uptake value ratios (SUVR) for all participants regional characteristics analyzed. Result population consisted 30 males 15 females mean age 65.9±8.2 years. Mean MMSE was 21.7±7.2 overall group. Five had features suggestive non‐AD type dementias excluded from further analyses. Visual examination F18‐Flutemetamol PET/MRI consistent continuum 29 cases, 9 them demonstrated normal metabolism, whereas 20 remaining cases showed F18‐FDG‐PET/MRI patterns characteristic (hypometabolism parieto‐temporal cortices and/or posterior cingulate cortex). In bivariate analysis, positively correlated temporal lobe gyrus (r= 0.382, p=0.020; r=0.330, p=0.046; respectively), additionally, significant negative correlation observed between designated score (r=‐0.461, p=0.004). Memory performance tested Enhanced Cued Recall (ECR) also associated 0.446, p=0.006), negatively ‐0.458, p=0.005). relationship ECR persisted when adjusted age, gender, year education (β=‐0.121, p=0.021) multivariate models. Conclusion General ability predicted markers deposition early‐stage disease. Further research should investigate predictive those rate decline. Acknowledgment: We acknowledge support GE Health Care [F18]flutemetamol doses.